Cytori Second Quarter Financial Results Update

Go back to Cytori Second Quarter Financial Results Update

Cytori Therapeutics (CYTX) Announces Kerastem Technologies Received FDA IDE Approval for STYLE Trial

July 28, 2015 8:09 AM EDT

Cytori Therapeutics (NASDAQ: CYTX) announced that Kerastem Technologies, a wholly owned subsidiary of Bimini Technologies, received U.S. Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to conduct a clinical trial studying the safety and feasibility of its technology for the treatment of female and early male pattern... More